Biotech | October 09, 2021
Cyprium Therapeutics and Sentynl, a Zydus subsidiary announce positive data for CUTX-101, CuHis
The rolling submission to the U.S. FDA will begin in the fourth quarter of this year
The rolling submission to the U.S. FDA will begin in the fourth quarter of this year
A growing number of studies have shown the benefit of a third dose of Covid-19 vaccine in immunocompromised subjects
The company plans to submit the IND application by the end of 2021
The listings aim to address global health priorities, identifying the medicines that provide the greatest benefits, and which should be available and affordable for all
Ampion is directly administered by inhalation and it allows the drug to directly target and attenuate inflammation in the lungs
The CASPIAN Phase III trial in extensive-stage small-cell lung cancer is the longest survival follow-up ever reported for immunotherapy treatment in this setting
If approved, Gavreto will be the first and only targeted treatment approved by the EMA that includes first-line treatment of people with RET fusion-positive advanced NSCLC
It approves tissue-based NGS companion diagnostic for Takeda's targeted therapy for NSCLC patients with EGFR Exon20 insertion mutations
RSV is a common and pervasive cause of severe acute respiratory illness in older adults with no vaccine currently available
The clinical trial will evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumours, and evaluate the anti-tumour efficacy of ICP-723 on NTRK fusion-positive cancers
Subscribe To Our Newsletter & Stay Updated
